Gavreto (pralsetinib) Now Indicated for RET-Mutant Thyroid Cancer
Recently, the FDA expanded treatment indications for Gavreto (pralsetinib). According to MedPage Today, the drug was previously indicated for the treatment of patients with lung cancers with RET gene fusions. Now, this…